In‐office balloon sinus dilation versus medical therapy for recurrent acute rhinosinusitis: a randomized, placebo‐controlled study

BSD plus MM proved superior to MM alone in enhancing QOL for RARS patients. BSD plus MM should be considered as a viable treatment option for properly diagnosed RARS patients.